This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klastersky, J. Articles by Barette, M. Search for Related Content PubMed Articles by Klastersky, J. Articles by Barette, M. Social Bookmarking                            What's this?

Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Score Predictive for Complications

Jean Klastersky, Marianne Paesmans, Aspasia Georgala, Frédérique Muanza, Barbara Plehiers, Laurent Dubreucq, Yassine Lalami, Michel Aoun, Martine Barette

From the Institut Jules Bordet, Brussels, Belgium.

Address reprint requests to Marianne Paesmans, MSc, Institut Jules Bordet, Rue Héger-Bordet, 1, B 1000, Bruxelles, Belgium; e-mail: marianne.paesmans{at}bordet.be

Purpose Since febrile neutropenic patients were recognized to constitute a heterogeneous population, several models have been developed for predicting the risk of serious medical complications. The Multinational Association for Supportive Care in Cancer score and its derived clinical prediction rules have been validated, but thus far there were no data about its use for simplifying therapy in predicted low-risk patients.

Patients and Methods In a single institution, we followed all episodes of febrile neutropenia between January 1999 and November 2003. Those patients predicted at low risk for complications, who were not receiving antibacterials at fever onset and were eligible for treatment with oral antibiotics, were treated with ciprofloxacin and amoxicillin-clavulanate and were discharged if they were clinically stable or improving after an initial observation period. The primary end point of the study was the rate of resolution of the febrile neutropenic episode without complications, among these early discharged patients.

Results Of 383 first febrile neutropenic episodes predicted at low risk of omplication, 178 patients (33 men and 145 women, mainly with solid tumors) were treated orally; they constituted the basis of our analysis. Seventy-nine patients (44%) were discharged early (with a median time to discharge of 26 hours); no complications occurred among them but three patients had to be readmitted, resulting in a success rate of 96% (95% CI, 92% to 100%).

Conclusion Our study shows that oral therapy followed by early discharge was feasible in a small but significant proportion of patients selected by a strategy combining predicted low risk and medical and nonmedical criteria.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. S. Elting, C. Lu, C. P. Escalante, S. H. Giordano, J. C. Trent, C. Cooksley, E. B.C. Avritscher, Y.-C. T. Shih, J. Ensor, B. N. Bekele, et al. Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia J. Clin. Oncol., February 1, 2008; 26(4): 606 - 611. [Abstract] [Full Text] [PDF]

				M.-J. Ouvrier, J.-C. Thery, and E. Blot Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients J. Clin. Oncol., December 10, 2006; 24(35): 5614 - 5614. [Full Text] [PDF]

				M. Paesmans and J. Klastersky In Reply J. Clin. Oncol., December 10, 2006; 24(35): 5614 - 5615. [Full Text] [PDF]